Johnson & Johnson Expects to Take a $600 Million Charge in Q2 (JNJ)

Johnson & Johnson (NYSE: JNJ) on Friday said that it plans to take a special charge of $600 million in the second quarter in order to boost its reserves for a possible settlement of civil lawsuits related to Risperdal, Invega, Natrecor and Omnicare.

Continue reading Johnson & Johnson Expects to Take a $600 Million Charge in Q2 (JNJ)

GlaxoSmithKline Extends Offer for Human Genome Sciences (GSK, HGSI)

GlaxoSmithKline (NYSE: GSK) has extended its $2.6 billion takeover offer for Human Genome Sciences (NASDAQ: HGSI) until the end of this month. The original tender period expired on June 7. GKS has now extended the tender period to June 29.

Continue reading GlaxoSmithKline Extends Offer for Human Genome Sciences (GSK, HGSI)